PT Medikaloka Hermina Tbk, (HEAL) Fair Value & Analysis
Healthcare · ID · Market cap 13.9T IDR
Fair value as of: Jul 12, 2026
From 14 valuation models · updated 28 days ago
Share price −14.8% over the past month.
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (419.29 IDR to 771.10 IDR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 765.00 IDR – 1,739 IDR · fair‑value band 419.29 IDR – 771.10 IDR · the 780.00 IDR price screens above the 598.99 IDR fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
PT Medikaloka Hermina Tbk, (HEAL) currently trades at 780.00 IDR, while our model-based Fair Value estimate is 598.99 IDR, implying the stock looks roughly 23.2% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PT Medikaloka Hermina Tbk, generated revenue of 7.2T IDR at a net margin of 5.6%. Revenue grew 5.4% year over year. It earns a return on equity of 7.8%. Net debt stands at 2.5T IDR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 419.29 IDR (bear case) to 771.10 IDR (bull case); at 780.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -23%, HEAL screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (616.88 IDR) versus Asset-Based (248.27 IDR). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia. The company offers services in the areas of medical acupuncture, pediatrics, surgery, plastic and reconstructive surgery, neurosurgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, …
Full company description
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia. The company offers services in the areas of medical acupuncture, pediatrics, surgery, plastic and reconstructive surgery, neurosurgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, obstetrics and gynecology, primary care family medicine, nuclear medicine and molecular theranostics, psychiatry, andrology, dietetics, lactation counseling, and dermatology and venereology. It also provides services in the areas of ophthalmology, clinical microbiology, pediatric neurology, occupational, radiation oncology, orthopedics and traumatology, pulmonology, anatomical pathology, clinical pathology, anesthesiology, internal medicine, psychology, radiology, physical medicine and rehabilitation, neurology, sports medicine specialist, aviation specialist, radiation specialist, otorhinolaryngology, occupational therapy, and urology. In addition, the company offers digital subtraction angiography, gastroenterology, IVF clinic, sleep and snoring clinic, pain clinic, growth and development clinic, stem cell, palliative care, perinatology ward, integrated stroke, and medical tourism services. Further, it is involved in investment, service, trading, management consulting, nurse training, and education services. PT Medikaloka Hermina Tbk was founded in 1985 and is headquartered in Jakarta Timur, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Medikaloka Hermina Tbk, reported revenue of 7.1T IDR in FY2025 versus 5.8T IDR in FY2021, a compound +5.2%/yr. Reported net income was 430B IDR in FY2025, compounding −19.0%/yr from FY2021.
HEAL screens 23% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Medikaloka Hermina Tbk, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Medikaloka Hermina Tbk, (HEAL) overvalued or undervalued?
What is the fair value of HEAL?
What is the quality score of HEAL?
What is the revenue of PT Medikaloka Hermina Tbk, (HEAL)?
What is the net profit margin of HEAL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Medikaloka Hermina Tbk, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.